CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today the receipt of two research grants to develop vaccines based on its proprietary Listeria platforms. These grants fund early-stage work to develop vaccines to both treat and prevent infections caused by HCV and HIV. The first grant, awarded to researches at Cerus and two collaborators from Johns Hopkins University (JHU) is entitled, “Development of Listeria-based Clinical Consensus HCV Vaccine Candidates.” This grant was received from the National Institute of Allergy and Infectious Disease, a division of the National Institutes of Health.
